pd-bioelectronic-medicine

Parkinson's Disease Bioelectronic Medicine Companies

Overview

Parkinson's Disease Bioelectronic Medicine Companies

Overview

Bioelectronic medicine (also called electroceuticals) represents an emerging frontier in Parkinson's disease treatment, using electrical stimulation to modulate neural circuits and restore motor and non-motor function. Unlike traditional pharmaceutical approaches, bioelectronic medicine targets specific neural pathways through implanted or non-invasive devices. This category covers companies developing bioelectronic approaches specifically for Parkinson's disease, including vagus nerve stimulation (VNS), spinal cord stimulation (SCS), and closed-loop neuromodulation systems.

The field builds on the success of deep brain stimulation (DBS) — now standard of care for advanced PD — but aims to offer less invasive alternatives with fewer surgical risks. Companies are pursuing multiple mechanisms: peripheral nerve stimulation to modulate central circuits, spinal cord stimulation to address gait and balance, and closed-loop systems that respond dynamically to patient symptoms.

Bioelectronic Medicine Mechanisms in PD

Vagus Nerve Stimulation (VNS)

The vagus nerve provides a bidirectional communication channel between peripheral organs and the brain. VNS activates cholinergic anti-inflammatory pathways, reduces neuroinflammation, and modulates dopaminergic circuits through brainstem projections. Non-invasive transcutaneous VNS (tVNS) offers a surgical-free alternative to implanted VNS devices.

Spinal Cord Stimulation (SCS)

SCS delivers electrical signals to the dorsal columns of the spinal cord, modulating sensory and motor circuits. For PD, SCS may improve gait, balance, and tremor by altering ascending and descending pathways. Closed-loop SCS systems that respond to patient movement in real-time represent the next generation of this approach.

Peripheral Nerve Stimulation

Targeting peripheral nerves (e.g., median, tibial) can modulate central nervous system activity through spinal cord projections. This approach offers minimally invasive alternatives for addressing PD symptoms.

Companies Developing Bioelectronic Approaches for PD

Saluda Medical

Saluda Medical is a medical technology company pioneering closed-loop spinal cord stimulation (SCS) systems. The company's flagship product, the Evoke® System, uses evoked compound action potentials (ECAPs) to sense and measure the spinal cord's response to stimulation in real-time, automatically adjusting therapy to maintain optimal neural activation.

| Attribute | Value |
|-----------|-------|
| Founded | 2010 |
| Headquarters | Sydney, Australia / Minneapolis, USA |
| Focus | Closed-loop spinal cord stimulation |
| Product | Evoke® System |
| Stage | Commercial (chronic pain) + clinical development (PD) |
| Website | [saludamedical.com](https://www.saludamedical.com/) |

Technology Platform

The Evoke System represents a fundamental advance in SCS technology:

• ECAP Sensing: First to record the spinal cord's response to stimulation in 2011, building on 15+ years of research
• Closed-Loop Control: Measures ECAPs in real-time and automatically adjusts stimulation amplitude to maintain consistent neural activation
• Objective Therapy: Removes "guesswork" from SCS programming by objectively measuring therapeutic effect

Saluda Medical is actively investigating closed-loop SCS for Parkinson's disease:

• Mechanistic Rationale: SCS can modulate ascending sensory pathways and descending motor pathways, potentially improving gait, balance, and tremor in PD
• Closed-Loop Advantage: Real-time ECAP sensing may allow the system to dynamically adjust stimulation based on patient movement and disease state
• Clinical Status: Parkinson's disease trials are ongoing, evaluating motor function, gait parameters, and quality of life outcomes

The Evoke System has demonstrated strong clinical data in chronic pain:

• EVOKE Study: Landmark clinical trial demonstrating superiority over traditional open-loop SCS
• 36-Month Data: Proven long-term relief out to 36 months
• 37+ Publications: Over 37 peer-reviewed publications and 200 scientific presentations
• Trillions of ECAPs: World's largest ECAP database demonstrating system reliability

Saluda Medical differentiates through:

• First to SENSE: Pioneer in neural sensing technology since 2010
• Closed-Loop Intelligence: Only system that objectively measures and adjusts therapy in real-time
• Extensive Clinical Data: Largest prospective, randomized controlled trial in SCS history

SetPoint Medical

SetPoint Medical is a medical device company developing an implantable neuroimmune modulation platform. The company's flagship product is the SetPoint System — the first and only FDA-approved implantable neuroimmune modulation device for treating rheumatoid arthritis.

| Attribute | Value |
|-----------|-------|
| Founded | 2012 |
| Headquarters | Valencia, California, USA |
| Focus | Implantable vagus nerve stimulation (VNS) |
| Product | SetPoint System |
| Stage | FDA-approved (RA) + clinical development (MS, PD) |
| Funding | $140M raised (August 2025) |
| Website | [setpointmedical.com](https://www.setpointmedical.com/) |

Technology Platform

The SetPoint System represents a novel approach to neuromodulation:

• Implantable Device: Small, wireless, implantable device that stimulates the vagus nerve
• Automatic Daily Therapy: Delivers therapy for one minute daily for up to ten years
• Neuroimmune Modulation: Activates the body's natural inflammatory control pathways through vagus nerve stimulation

• FDA Approval: First and only FDA-approved implantable neuroimmune modulation device for moderately to severely active rheumatoid arthritis (RA) in adults who have had inadequate response to biologic or targeted synthetic DMARDs
• CMS Coverage: Transitional pass-through payment approved (November 2025)

SetPoint's VNS technology has potential applications in Parkinson's disease:

• Neuroinflammation Reduction: VNS activates the cholinergic anti-inflammatory pathway, reducing peripheral and central inflammation — a key driver of PD progression
• Modulation of Dopaminergic Circuits: VNS projects to brainstem nuclei that influence basal ganglia function
• Autonomic Function: May improve autonomic dysfunction in PD, including gastrointestinal symptoms
• Future Development: The company has received FDA IDE approval for a pilot study in relapsing-remitting multiple sclerosis, indicating expansion beyond RA

The SetPoint System works through multiple pathways relevant to PD:

Galvani Bioelectronics

Galvani Bioelectronics is a precision neuromodulation company registered in England & Wales. The company is a joint venture between GlaxoSmithKline (GSK) and Verily Life Sciences (formerly Google Life Sciences), formed to develop bioelectronic medicines.

| Attribute | Value |
|-----------|-------|
| Founded | 2016 |
| Headquarters | Stevenage, UK (GSK Medicines Research Centre) |
| Focus | Precision neuromodulation |
| Parent Companies | GSK, Verily (Google) |
| Stage | Clinical development |
| Website | [galvani.bio](https://galvani.bio/) |

Technology Platform

Galvani develops implanted devices that modulate specific peripheral nerves to treat chronic conditions:

• Precision Targeting: Focuses on specific nerve targets relevant to disease pathways
• Miniaturized Implants: Developing small, long-lived implantable devices
• Programmable Therapy: Adjustable stimulation parameters for individual patient needs

Galvani's current lead program is splenic nerve stimulation for rheumatoid arthritis:

• Mechanism: Stimulating the splenic nerve modulates the immune system, reducing inflammatory responses
• Clinical Status: Investigational device limited to clinical investigation in UK/EU
• Regulatory: Caution: Investigational device limited by US Federal law to investigational use

While Galvani's current focus is on RA, their platform technology has potential PD applications:

• Peripheral Neuromodulation: The company's approach to targeting specific peripheral nerves could be adapted for PD
• Autonomic Modulation: Vagal and other autonomic nerve targets may address non-motor PD symptoms
• Research Pipeline: The company has stated interest in expanding beyond immunology to neurological conditions

Galvani represents a unique partnership model:

• GSK Expertise: Pharmaceutical development, clinical trial design, regulatory navigation
• Verily Expertise: miniaturized electronics, software, data analytics
• Combined Capabilities: End-to-end capability from device development through clinical translation

electroCore (Non-Invasive VNS)

electroCore develops non-invasive neuromodulation therapies, primarily transcutaneous vagus nerve stimulation (tVNS). While covered in detail in the [electroCore](/companies/electrocore) company page, the company's PD program is relevant here.

| Attribute | Value |
|-----------|-------|
| Founded | 2005 |
| Headquarters | Basking Ridge, New Jersey, USA |
| Stock | NASDAQ: ECOR |
| Focus | Non-invasive VNS (tVNS) |
| Product | gammaCore |
| Stage | Commercial + clinical development |
| Website | [electrocore.com](https://www.electrocore.com) |

PD Development Status

electroCore is actively investigating tVNS for Parkinson's disease:

• Mechanistic Rationale: Multiple studies suggest VNS may improve motor function through reduction of neuroinflammation, modulation of basal ganglia circuitry, and improvement of gait and postural control
• Clinical Evidence: Trials have shown improvements in motor scores (UPDRS), gait parameters, postural stability, and autonomic function
• Non-Invasive Advantage: No surgical implantation required, reducing risk and enabling broader patient access

Emerging Companies and Pipeline

Companies with PD Potential

Several additional companies are developing bioelectronic approaches with potential PD applications:

| Company | Technology | PD Status | Notes |
|---------|------------|-----------|-------|
| SecondWave Systems | Transcranial electrical stimulation (tES) | Investigational | Non-invasive approach |
| H4 Neuro | Vagus nerve stimulation | Development | Targeted at neurological conditions |
| NeuroPace | Responsive neurostimulation | Investigational | RNS system being explored for movement disorders |

Technology Development Stages

| Company | Product | Technology | Development Stage | Target Indication |
|---------|---------|------------|-------------------|-------------------|
| Saluda Medical | Evoke® | Closed-loop SCS | Clinical trials | PD (gait, balance) |
| SetPoint Medical | SetPoint System | Implantable VNS | FDA-approved (RA), IDE (MS) | Expansion to PD |
| Galvani Bioelectronics | TBD | Precision neuromodulation | Clinical (RA) | Future PD development |
| electroCore | gammaCore | Non-invasive tVNS | Clinical development | PD (investigational) |

Clinical Evidence

VNS for PD

Multiple clinical studies have evaluated VNS for Parkinson's disease:

• Motor Function: Some studies show improvements in UPDRS motor scores
• Gait and Balance: VNS may improve postural stability and gait parameters
• Non-Motor Symptoms: Autonomic function improvements, including gastrointestinal symptoms
• Neuroinflammation: Biomarker studies show reduction in inflammatory markers

SCS for PD

Spinal cord stimulation for PD is an emerging application:

• Gait Improvement: Open-label studies show improvements in gait and freezing of gait
• Balance Enhancement: SCS may improve postural stability
• Closed-Loop Advantages: Real-time adjustment may provide more consistent benefit
• Ongoing Trials: Multiple trials evaluating SCS for PD motor complications

Regulatory Landscape

FDA Pathways

• IDE (Investigational Device Exemption): Required for clinical trials
• Breakthrough Device Designation: Available for devices addressing unmet needs
• 510(k) Clearance: For devices demonstrating substantial equivalence
• PMA (Premarket Approval): For Class III devices

Reimbursement

• DBS for PD is covered by Medicare and most private insurers
• Emerging bioelectronic devices are pursuing similar coverage pathways
• CPT codes exist for VNS implantation and programming

Investment and Funding

Notable Funding in Bioelectronics for PD

| Company | Funding | Year | Focus |
|---------|---------|------|-------|
| SetPoint Medical | $140M | August 2025 | VNS platform expansion |
| Saluda Medical | Extensive | Multiple rounds | Closed-loop SCS |
| Galvani Bioelectronics | Initial joint venture | 2016 | Platform development |

Market Potential

The bioelectronic medicine market for neurological disorders is projected to grow significantly:

• Neuromodulation devices for PD: $500M-$1B by 2030
• Non-invasive neuromodulation: $2-4B by 2030
• Closed-loop systems: Premium segment growth

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Neurotechnology](/companies/pd-neurotechnology)
• [Deep Brain Stimulation](/technologies/deep-brain-stimulation)
• [Vagus Nerve Stimulation](/therapeutics/vagus-nerve-stimulation)
• [Spinal Cord Stimulation](/technologies/spinal-cord-stimulation)
• [Neuromodulation](/therapeutics/neuromodulation)
• [electroCore](/companies/electrocore)

External Links

• [SetPoint Medical](https://www.setpointmedical.com/)
• [Saluda Medical](https://www.saludamedical.com/)
• [Galvani Bioelectronics](https://galvani.bio/)
• [electroCore](https://www.electrocore.com)
• [NASDAQ: ECOR](https://www.nasdaq.com/market-activity/stocks/ecor)

References